This Advisory, based on TIP 49, Incorporating Alcohol Pharmacotherapies Into Medical Practice, focuses on medication and related treatment decisions made after screening and assessment for AUD, and medically supervised withdrawal, if necessary. Alcohol consumption should not stop abruptly in those patients who have consumed alcohol regularly over a prolonged period of time. This Advisory is meant as an overview of AUD medications to facilitate abstinence.
Dashboard: Filter Bricks
Main page content
Displaying results 1 - 3 of 3
![Advisory: Prescribing Pharmacotherapies for Patients With Alcohol Use Disorder (based on TIP 49)](/sites/default/files/styles/product_thumbnail_dashboard/public/PEP20-02-02-015.jpg?itok=_uin3Frk)
Publication ID: PEP20-02-02-015
Published:
![TIP 49: Incorporating Alcohol Pharmacotherapies Into Medical Practice](/sites/default/files/styles/product_thumbnail_dashboard/public/sma13-4380.jpg?itok=Shdd1qE1)
Publication ID: SMA13-4380
Published:
This manual provides clinical practice guidelines for using medications in the medication-assisted treatment of alcohol use disorder. It offers guidance on prescribing acamprosate, disulfiram, oral naltrexone, and extended-release injectable naltrexone. The manual also discusses patient management. Access the literature review.
![Quick Guide for Counselors Based on TIP 49](/sites/default/files/styles/product_thumbnail_dashboard/public/sma10-4542.jpg?itok=TaBJTbG5)
Publication ID: SMA10-4542
Published:
This manual guides counselors in the use of medications to help clients achieve abstinence from alcohol. It describes how the medications work and whom may benefit. It also presents the side effects of three FDA-approved medications: acamprosate, disulfiram, and naltrexone.